Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
filingDate |
2014-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101839665-B1 |
titleOfInvention |
Oral formulation for the treatment of cardiovascular diseases |
abstract |
The present invention relates to pharmaceutical compositions comprising HMG-CoA reductase inhibitors, especially statins and acetylsalicylic acid, in a manner that minimizes the interaction of statins and acetylsalicylic acid for use in the prevention or treatment of cardiovascular diseases. |
priorityDate |
2013-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |